HYBIO(SZ:300199)2023-08-14 16:00Environmental Compliance - The company reported a total discharge of 60.902 tons of hazardous waste in 2022, complying with national hazardous waste regulations[14]. - The company achieved a COD discharge of 0.57914 tons, meeting the standard of 300 mg/L[14]. - The company has a valid pollution discharge permit until April 25, 2027, following the renewal completed in March 2022[12]. - The company’s wastewater treatment processes consistently meet the discharge standards for various pollutants, including BOD at 4 mg/L and total nitrogen at 15 mg/L[14]. - The company’s wastewater discharge includes parameters such as pH between 6-9 and total phosphorus at 0.2 mg/L, all within regulatory limits[14]. - Shenzhen Hanyu Pharmaceutical Co., Ltd. achieved wastewater treatment compliance with BOD at 6.8 mg/L, below the limit of 150 mg/L, resulting in a total discharge of 0.00012 tons[15]. - The company reported a total phosphorus level of 0.33667 mg/L in treated wastewater, significantly below the 7 mg/L limit, with a total discharge of 1.13166 tons[15]. - The company processed 128.912 tons of hazardous waste in the Nanshan branch, adhering to national hazardous waste regulations[16]. - The company maintained compliance with wastewater discharge standards, with COD levels at 7.55716 mg/L, well below the 345 mg/L limit, resulting in a discharge of 0.03396 tons[16]. - The company’s noise levels were recorded at 58.4/48.4 mg/Nm3, compliant with the daytime and nighttime limits of 65/55 mg/Nm3[16]. - The company’s wastewater treatment facility is equipped with online monitoring for key indicators including COD, ammonia nitrogen, total nitrogen, total phosphorus, pH, and flow[18]. - The company’s wastewater treatment results consistently met standards, as confirmed by self-monitoring protocols[21]. - The company updated its emergency response plan for environmental incidents in August 2021, ensuring preparedness for potential environmental events[22]. - The company’s wastewater treatment process achieved compliance with ammonia nitrogen levels at 4.16371 mg/L, below the 35 mg/L limit, with a total discharge of 0.01871 tons[16]. - In the first half of 2023, the company invested over 3.43 million RMB in environmental protection expenses, including 1,567 RMB in environmental protection tax[35]. - The company invested 480,000 RMB in environmental protection measures and paid 2,139.76 RMB in environmental protection tax in the first half of 2023[23]. Corporate Governance and Financial Reporting - The half-year financial report has not been audited, indicating that the figures may be subject to change upon final review[47]. - The financial report emphasizes the commitment to accurate and complete financial disclosures, as stated by the company's management[115]. - The company continues to comply with regulatory requirements for financial reporting and disclosures[115]. - The report includes a comprehensive overview of the company's governance and social responsibility initiatives[117]. - The report is available for review at the company's securities management department[120]. - All directors attended the board meeting to review the semi-annual report[138]. Financial Performance - The company's operating revenue for the reporting period was ¥325,278,801.43, a decrease of 8.77% compared to the same period last year[137]. - The net profit attributable to shareholders was -¥34,133,703.88, an improvement of 65.25% from -¥98,223,075.25 in the previous year[137]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥106,372,963.05, a decline of 257.26% compared to -¥29,774,600.47 last year[137]. - The net cash flow from operating activities was -¥37,660,161.00, a significant decrease of 220.82% from ¥31,170,243.64 in the previous year[137]. - The total assets at the end of the reporting period were ¥3,495,397,141.24, down 3.21% from ¥3,611,233,247.62 at the end of the previous year[137]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,261,019,876.94, a decrease of 0.76% from ¥1,270,636,709.44 at the end of the previous year[137]. - The basic and diluted earnings per share were both -¥0.04, an improvement of 63.64% from -¥0.11 in the same period last year[137]. - The weighted average return on equity was -2.70%, an improvement of 3.59% from -6.29% in the previous year[137]. - The company plans not to distribute cash dividends or issue bonus shares[139]. Market Position and Product Development - The company operates in the pharmaceutical manufacturing industry, which is characterized by weak cyclicality and is expected to see continued growth due to increasing healthcare demand driven by factors such as aging population and rising disposable income[37]. - The company specializes in peptide drug research, production, and sales, leveraging advanced automated peptide synthesis and purification systems to maintain a competitive edge in both domestic and international markets[38]. - The main products include peptide raw materials and formulations, with a strategic focus on four therapeutic areas: reproductive health, digestive bleeding, weight loss, and infection control[39]. - The company holds a 76.78% market share in the domestic market for its injection of terlipressin, which is recommended as a first-line treatment for complications related to liver cirrhosis[44]. - The company has developed a comprehensive range of injectable products, including somatostatin and terlipressin, which are recognized in various clinical guidelines for their effectiveness in treating specific medical conditions[43][44]. - The company aims to optimize its product structure and enhance strategic resilience to maintain its leading position in the peptide drug industry[38]. - The company has 26 peptide drugs, 9 new drug certificates, and 24 clinical approvals, indicating a strong product pipeline[178]. - The company achieved a significant market share in domestic peptide drugs, particularly in products like Liraglutide and Semaglutide, which are recognized internationally for their high technical difficulty[179]. - The company has passed or deemed to have passed consistency evaluations for 15 generic drugs, including 10 peptide injections and 5 small molecule solid preparations, leading the industry in evaluation numbers[179]. - The company continues to advance its product registration in both domestic and international markets, with the approval of Acetate Octreotide Injection in January 2023[182]. - The company is actively pursuing strategic partnerships to enhance its international market presence and product offerings[176]. - The company has established a comprehensive R&D platform, collaborating with various research institutions to support its innovative drug development[177]. - The company is focused on expanding its market strategy by leveraging its product quality and technological advantages[176]. - The company aims to maintain a competitive edge through continuous product development and strategic partnerships[195]. Shareholder and Capital Management - The company approved the cancellation of 33,685,704 repurchased shares, reducing total share capital from 916,927,040 shares to 883,241,336 shares[88]. - The company completed the business registration change and obtained a new business license on April 17, 2023, following the share cancellation[98]. - The total amount of external guarantees approved during the reporting period is 0, while the actual amount of guarantees provided is 12,500,000 yuan, with a total guarantee balance of 42,700,000 yuan at the end of the reporting period[78]. - The actual total amount of guarantees provided accounts for 95.24% of the company's net assets[80]. - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[46]. - There are no significant related party transactions or major contracts during the reporting period[81]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[68]. - The company has no significant litigation cases that meet the materiality standards during the reporting period[65]. - The company has not conducted any joint external investments during the reporting period[69]. - The company has no significant leasing situations during the reporting period[75]. - The company has no significant related party debts or financial transactions with related financial companies[70]. - The company has no other major related transactions during the reporting period[73]. - The company has not issued new shares or conducted stock splits during this reporting period[107]. Product Quality and Certifications - The company has achieved multiple certifications, including FDA and EU GMP, ensuring high-quality management standards[195]. - The company has obtained the EU GMP certification for its injection production line, which allows its products to continue entering the EU market, positively impacting future operating performance[83]. - The production model is based on "sales-driven production + minimal stock," ensuring timely delivery and quality control through various GMP certifications[189]. - The marketing structure has been optimized to enhance efficiency and coverage in various regional markets[195]. - The company emphasizes a comprehensive quality management system, ensuring 100% compliance with production standards and training[195]. - The company launched upgraded peptide skincare products under the brand "Boshuyan" and successfully marketed antibacterial agents "Hanqu" and "Hanf" through various online platforms[106]. - The company is focusing on expanding its product offerings based on market needs, leveraging its technological advantages in the peptide industry[106].